Vatalanib
... that Vatalanib, an anti-cancer drug currently in clinical trials, inhibits the growth of new blood vessels by selectively blocking receptors of vascular endothelial growth factors?
... that <b id="mwAlg"><a href="./Vatalanib" id="mwAlk" rel="mw:WikiLink" title="Vatalanib">Vatalanib</a></b>, an anti-<a href="./Cancer" id="mwAlo" rel="mw:WikiLink" title="Cancer">cancer</a> drug currently in <a href="./Clinical_trial" id="mwAls" rel="mw:WikiLink" title="Clinical trial">clinical trials</a>, <a href="./Angiogenesis_inhibitor" id="mwAlw" rel="mw:WikiLink" title="Angiogenesis inhibitor">inhibits</a> the <a href="./Angiogenesis" id="mwAl0" rel="mw:WikiLink" title="Angiogenesis">growth of new blood vessels</a> by selectively blocking <a class="mw-redirect" href="./VEGF_receptors" id="mwAl4" rel="mw:WikiLink" title="VEGF receptors">receptors</a> of <a href="./Vascular_endothelial_growth_factor" id="mwAl8" rel="mw:WikiLink" title="Vascular endothelial growth factor">vascular endothelial growth factors</a>?